Novartis Stock Hits New 52-Week High (NVS)

NEW YORK ( TheStreet) -- Novartis (NYSE: NVS) hit a new 52-week high Friday as it is currently trading at $59.27, above its previous 52-week high of $59.25 with 394,179 shares traded as of 10:30 a.m. ET. Average volume has been 1.8 million shares over the past 30 days.

Novartis has a market cap of $140.92 billion and is part of the health care sector and drugs industry. Shares are up 2.3% year to date as of the close of trading on Thursday.

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. The company has a P/E ratio of 15.4, below the average drugs industry P/E ratio of 16.4 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Novartis Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes